RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to "Buy" Rating

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) was upgraded by equities research analysts at HC Wainwright from a "neutral" rating to a "buy" rating in a note issued to investors on Thursday, MarketBeat Ratings reports. The firm currently has a $10.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 452.49% from the company's current price.

Several other analysts have also issued reports on RAPT. JPMorgan Chase & Co. lowered RAPT Therapeutics from a "neutral" rating to an "underweight" rating in a report on Monday, November 11th. Wells Fargo & Company decreased their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an "overweight" rating for the company in a research report on Tuesday, November 12th. Stifel Nicolaus reaffirmed a "hold" rating and set a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Piper Sandler downgraded RAPT Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $8.00 to $2.00 in a research note on Monday, November 11th. Finally, UBS Group decreased their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a "neutral" rating for the company in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $9.56.

RAPT Therapeutics Stock Performance

Shares of NASDAQ RAPT traded up $0.08 during trading hours on Thursday, reaching $1.81. 9,733,712 shares of the stock were exchanged, compared to its average volume of 1,349,399. The firm has a market capitalization of $63.27 million, a price-to-earnings ratio of -0.65 and a beta of 0.07. The stock's fifty day simple moving average is $1.50 and its 200 day simple moving average is $2.19. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.09. Research analysts predict that RAPT Therapeutics will post -2.86 EPS for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

Institutional investors have recently made changes to their positions in the stock. Readystate Asset Management LP purchased a new stake in RAPT Therapeutics in the 3rd quarter worth approximately $36,000. Bank of New York Mellon Corp raised its stake in shares of RAPT Therapeutics by 24.0% during the second quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company's stock worth $349,000 after acquiring an additional 22,175 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. Barclays PLC grew its holdings in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its position in RAPT Therapeutics by 66.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company's stock worth $258,000 after purchasing an additional 33,692 shares during the period. Hedge funds and other institutional investors own 99.09% of the company's stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.